COMPASS Pathways plc (NASDAQ:CMPS) Shares Bought by Conservest Capital Advisors Inc.

Conservest Capital Advisors Inc. increased its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 28.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,363 shares of the company’s stock after purchasing an additional 3,000 shares during the period. Conservest Capital Advisors Inc.’s holdings in COMPASS Pathways were worth $51,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Sio Capital Management LLC grew its position in shares of COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after purchasing an additional 621,222 shares during the period. Rosalind Advisors Inc. grew its position in shares of COMPASS Pathways by 6.5% in the third quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock valued at $4,923,000 after purchasing an additional 47,423 shares during the period. Polar Asset Management Partners Inc. grew its position in shares of COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after purchasing an additional 258,000 shares during the period. Acuta Capital Partners LLC purchased a new stake in shares of COMPASS Pathways in the third quarter valued at $2,435,000. Finally, Walleye Capital LLC purchased a new stake in shares of COMPASS Pathways in the third quarter valued at $2,126,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CMPS. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Stifel Nicolaus began coverage on COMPASS Pathways in a research report on Thursday. They issued a “buy” rating and a $11.00 price objective for the company. Canaccord Genuity Group lowered their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Maxim Group lowered their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, HC Wainwright lowered their price target on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $21.83.

COMPASS Pathways Trading Up 0.3 %

Shares of CMPS opened at $3.93 on Friday. The stock’s 50-day moving average is $4.06 and its two-hundred day moving average is $5.26. The stock has a market cap of $268.89 million, a PE ratio of -1.79 and a beta of 2.28. COMPASS Pathways plc has a 12 month low of $3.16 and a 12 month high of $12.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). Equities analysts forecast that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.